Citizens analyst Constantine Davides lowered the firm’s price target on Evolent Health (EVH) to $10 from $11 and keeps an Outperform rating on the shares. The firm’s updated model reflects more conservative operating margin assumptions for 2026-2027, as Evolent contends with the potential erosion of customer ACA membership in 2026, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health Completes Stock Purchase Agreement
- Evolent Health Appoints Jill Smith to Board
- Evolent Health price target lowered to $9.50 from $11.50 at Citi
- Evolent Health: Overly Pessimistic Valuation Presents a Buy Opportunity Amidst Exaggerated Concerns
- Evolent Health price target lowered to $7 from $13 at JPMorgan